Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.9200
+0.0225 (2.51%)
At close: Oct 9, 2025, 4:00 PM EDT
0.9100
-0.0100 (-1.09%)
Pre-market: Oct 10, 2025, 7:34 AM EDT
Immunic Employees
Immunic had 91 employees as of December 31, 2024. The number of employees increased by 14 or 18.18% compared to the previous year.
Employees
91
Change (1Y)
14
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$1,119,077
Market Cap
90.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Dec 31, 2021 | 55 | 27 | 96.43% |
| Dec 31, 2020 | 28 | 2 | 7.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMUX News
- 9 days ago - Immunic to Participate in Scientific and Investor Conferences in October - PRNewsWire
- 15 days ago - Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - PRNewsWire
- 4 weeks ago - Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - PRNewsWire
- 5 weeks ago - Immunic to Participate in Investor and Scientific Conferences in September - PRNewsWire
- 2 months ago - Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis - PRNewsWire
- 4 months ago - Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted - Seeking Alpha
- 4 months ago - Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - PRNewsWire